Semanteon Capital Management LP Purchases 1,840 Shares of Natera, Inc. (NASDAQ:NTRA)

Semanteon Capital Management LP increased its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 25.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,027 shares of the medical research company's stock after acquiring an additional 1,840 shares during the quarter. Semanteon Capital Management LP's holdings in Natera were worth $1,429,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP boosted its holdings in shares of Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock valued at $355,493,000 after purchasing an additional 1,883,481 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Natera in the fourth quarter worth about $146,419,000. PointState Capital LP boosted its stake in Natera by 112.0% during the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company's stock valued at $99,343,000 after buying an additional 413,468 shares during the last quarter. Franklin Resources Inc. grew its holdings in Natera by 42.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company's stock valued at $144,958,000 after buying an additional 328,375 shares in the last quarter. Finally, Maverick Capital Ltd. increased its stake in Natera by 25.2% in the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company's stock worth $170,119,000 after acquiring an additional 269,706 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 24,861 shares of the firm's stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the transaction, the insider now owns 140,684 shares of the company's stock, valued at approximately $23,208,639.48. This trade represents a 15.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the sale, the chief executive officer now owns 203,354 shares of the company's stock, valued at approximately $29,160,963.60. This represents a 30.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 306,797 shares of company stock worth $48,940,883 in the last ninety days. 7.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research reports. Royal Bank of Canada started coverage on Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price for the company. Barclays started coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and set a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Sanford C. Bernstein lifted their price target on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, January 10th. Finally, Robert W. Baird boosted their price objective on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $178.12.

Natera Trading Up 0.5 %

Shares of NASDAQ NTRA traded up $0.75 during mid-day trading on Tuesday, reaching $154.58. The company had a trading volume of 1,081,640 shares, compared to its average volume of 1,338,057. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The business's 50-day moving average is $160.92 and its 200-day moving average is $150.26. The stock has a market cap of $20.90 billion, a price-to-earnings ratio of -87.83 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.